Should gain-of-function research on dangerous pathogens be permitted under strict biosafety protocols to develop medical countermeasures?
3 peer-reviewed studies for, 2 against
Key takeaways
The verdict finds the case against permitting gain-of-function research on potential pandemic pathogens stronger, citing the precautionary principle.
2012 ferret studies showed specific mutations can let H5N1 bird flu spread by respiratory droplets, data supporters say aids surveillance and vaccines.
Supporters argue that, with risk-benefit frameworks, the research can improve understanding of disease and help develop medical countermeasures.
Critics say benefits are largely speculative because natural viral evolution is unpredictable, while the risk of a lab escape is concrete and potentially global.
Recent analyses describe weaknesses in current oversight and call for stronger regulation, layered review and fuller assessment of societal risks.
Stronger evidence: Against
Verdict
The debate over Gain-of-Function (GoF) research on potential pandemic pathogens (PPPs) presents a conflict between high-reward scientific foresight and high-risk existential safety. The "against" side is ultimately stronger due to the precautionary principle: while the benefits of creating transmissible avian flu or enhanced coronaviruses are largely speculative—specifically regarding the timeline and accuracy of vaccine development—the risks are concrete and potentially global. Quantitative risk assessments, such as those by Lipsitch and Klous, demonstrate that even with BSL-4 containment, the probability of a laboratory-acquired infection (LAI) escaping into the community is statistically significant over time. Proponents argue that GoF research provides a "map" of viral evolution, but critics successfully point out that nature’s evolutionary pathways are vast and unpredictable, making these maps often irrelevant for the next natural spillover. Furthermore, the availability of safer alternatives, such as "loss-of-function" studies, inactivated virus research, and computational modeling, undermines the necessity of creating novel, highly contagious pathogens. In a world where a single breach could trigger a pandemic, the consensus among many biosecurity experts is that the marginal gains in medical countermeasures do not justify the catastrophic risk of an engineered pandemic.
Masaki Imai, Tokiko Watanabe et al. · 1,474 citations
Research showing how specific mutations allow H5N1 to spread among mammals, which is essential for identifying high-risk viral strains in nature and developing vaccines.
Critical analysis of the P3CO Framework showing its weaknesses in oversight of gain-of-function research with potential pandemic pathogens, recommending stronger biosafety and biosecurity protocols with new regulatory structures and comprehensive risk assessments.
Masaki Imai, Tokiko Watanabe et al. · 1,474 citations
Research showing how specific mutations allow H5N1 to spread among mammals, which is essential for identifying high-risk viral strains in nature and developing vaccines.
Sander Herfst, Eefje J. A. Schrauwen et al. · 1,428 citations
This landmark study demonstrated that H5N1 could become transmissible via respiratory droplets, providing critical data for pandemic preparedness and surveillance.
Selgelid provides a comprehensive ethical analysis of gain-of-function research, examining how it can improve understanding of disease pathogenesis and develop medical countermeasures while addressing biosecurity and biosafety risks through risk-benefit assessment frameworks.
Critical analysis of the P3CO Framework showing its weaknesses in oversight of gain-of-function research with potential pandemic pathogens, recommending stronger biosafety and biosecurity protocols with new regulatory structures and comprehensive risk assessments.
Recent article proposing ethical criteria and layered review processes for assessing societal consequences of dangerous gain-of-function research. Discusses implications of the 2025 executive order establishing a federal funding pause on DGoF research and emphasizes need for rigorous evaluation of significant societal consequences alongside biosafety protocols.
The debate
Michael: We cannot afford to wait for the next pandemic to happen before we understand how a virus might jump to humans. The Fouchier and Kawaoka studies in 2012 were a wake-up call. By identifying the exact mutations that allow H5N1 to spread via respiratory droplets, we gave the global health community a target for surveillance. If we don’t know what the enemy looks like, we can’t build a defense.
Christopher: But Michael, you aren’t just identifying the enemy; you’re creating it. The risk of a lab leak is not a theoretical ghost—it’s a statistical certainty over a long enough timeline. The 2014 analysis in PLOS Medicine showed that these experiments offer almost no practical advantage for vaccine design that can’t be achieved through safer means. You are gambling with the lives of billions for a marginal increase in academic knowledge.
Michael: It’s more than academic. Strict biosafety protocols like BSL-3 and BSL-4 are designed precisely to handle these risks. These facilities have multiple redundancies, from air filtration to strict decontamination. If we permit this research under global oversight, we can develop countermeasures before a virus naturally evolves these traits in the wild. Nature is already running its own gain-of-function experiments every day in bird markets and pig farms.
Christopher: Nature doesn’t have a central laboratory where a single mistake can be amplified by modern air travel. Even the most "secure" labs have a human element, and humans make mistakes. The Eurosurveillance risk assessment from 2014 calculated that the risk of a community outbreak from a lab leak is unacceptably high. When the stakes are a global pandemic, a "strict protocol" isn’t enough because "strict" doesn’t mean "perfect." One infected scientist walking out those doors is all it takes.
Michael: So your solution is to stay blind? If we stop this research, we won’t know which mutations to look for in our surveillance. We’ll be caught off guard just like we have been in the past. We need to empower science to stay ahead of the curve.
Christopher: We stay ahead by focusing on broad-spectrum antivirals and universal vaccines that work against whole families of viruses, rather than chasing specific engineered mutations that might never appear in nature. We should be building a shield that works against everything, not spending our resources making the sword sharper and hoping we don’t drop it on ourselves.
Michael: The data from those "sharper swords" is exactly what informs the design of the "universal shields" you want. You can’t have one without the other.
Christopher: You can, and you must. The risk-benefit ratio simply doesn’t close in your favor. Science must have boundaries when its failure modes include global catastrophe.
Frequently asked questions
What is gain-of-function research on dangerous pathogens?
It refers to experiments that give a pathogen new or enhanced abilities, such as greater transmissibility. Examples include 2012 studies that made H5N1 bird flu transmissible between ferrets by respiratory droplets.
Does gain-of-function research help develop vaccines?
Supporters say it shows which mutations could make viruses dangerous, which may help identify high-risk strains and prepare vaccines. Critics counter that these benefits are largely speculative, especially regarding the timing and accuracy of vaccine development.
Can strict biosafety protocols prevent a lab leak?
According to the verdict, quantitative risk assessments indicate that even with BSL-4 containment, the chance of a lab-acquired infection spreading into the community is significant over time. Critics also argue that current oversight frameworks have weaknesses.
Are there safer alternatives to gain-of-function research?
Critics point to loss-of-function studies, research using inactivated viruses and computational modeling as options that do not require creating novel, highly contagious pathogens.